Subtopic Deep Dive
Dynamic International Prognostic Scoring System for Myelofibrosis
Research Guide
What is Dynamic International Prognostic Scoring System for Myelofibrosis?
The Dynamic International Prognostic Scoring System (DIPSS) for myelofibrosis is a time-dependent risk model predicting survival in primary myelofibrosis patients using age, hemoglobin, white blood cell count, blasts, and symptoms.
DIPSS refines the International Prognostic Scoring System by allowing updates as clinical variables change during follow-up (Passamonti et al., 2009, Blood, 951 citations). It identifies low-, intermediate-1, intermediate-2, and high-risk groups with median survivals of 15.4, 6.5, 2.9, and 1.3 years. Over 20 studies validate DIPSS in myelofibrosis cohorts.
Why It Matters
DIPSS guides risk-adapted therapy in myelofibrosis, stratifying patients for allogeneic transplantation timing and eligibility for trials of JAK inhibitors like ruxolitinib (Tefferi, 2020). It incorporates transfusion dependence and cytogenetics in DIPSS-plus extensions, improving decisions on novel agents such as pacritinib (Mascarenhas et al., 2018). Accurate prognostication reduces overtreatment in low-risk patients and accelerates high-risk referrals, impacting survival in 10,000+ annual myelofibrosis cases worldwide (Passamonti et al., 2009; Tefferi et al., 2014).
Key Research Challenges
Molecular Integration
Incorporating mutations like CALR and ASXL1 into DIPSS remains inconsistent across studies (Tefferi et al., 2014). Current models underperform in post-PV/ET myelofibrosis subtypes (Passamonti et al., 2017). Over 570 patients analyzed show need for unified clinical-molecular scores.
Blast Transformation Prediction
DIPSS poorly predicts leukemic evolution despite blasts as a factor (Tefferi et al., 2014). Molecularly annotated cohorts reveal JAK2/CALR/MPL inform leukemia-free survival but lack dynamic updates. Long-term studies of 1,000+ patients highlight this gap.
Cytokine Prognostic Value
Elevated IL-8, IL-2R, IL-12, IL-15 independently predict outcomes beyond DIPSS (Tefferi et al., 2011). Profiling 100+ cytokines in PMF cohorts identifies therapeutic targets but integration into dynamic models lags. Validation in larger trials is needed.
Essential Papers
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti, Francisco Cervantes, Alessandro M. Vannucchi et al. · 2009 · Blood · 951 citations
Abstract Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms ha...
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson et al. · 2014 · Blood · 709 citations
Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostical...
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Ayalew Tefferi, Elisa Rumi, Guido Finazzi et al. · 2013 · Leukemia · 650 citations
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi, Rakhee Vaidya, Domenica Caramazza et al. · 2011 · Journal of Clinical Oncology · 576 citations
Purpose Abnormal cytokine expression accompanies myelofibrosis and might be a therapeutic target for Janus-associated kinase (JAK) inhibitor drugs. This study describes the spectrum of plasma cytok...
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi et al. · 2018 · Leukemia · 537 citations
Calreticulin and cancer
Jitka Fučíková, Radek Špíšek, Guido Kroemer et al. · 2020 · Cell Research · 363 citations
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
John Mascarenhas, Ronald Hoffman, Moshe Talpaz et al. · 2018 · JAMA Oncology · 356 citations
clinicaltrials.gov Identifier: NCT02055781.
Reading Guide
Foundational Papers
Start with Passamonti et al. (2009, Blood, 951 citations) for DIPSS definition and variables; follow Tefferi et al. (2014, 709 citations) for molecular prognostication in 570 PMF patients.
Recent Advances
Tefferi (2020, American Journal of Hematology, 287 citations) for 2021 PMF update with DIPSS context; Passamonti et al. (2017, Leukemia, 322 citations) for post-PV/ET models.
Core Methods
Cox regression for dynamic scoring; variables weighted by hazard ratios; extensions use cytogenetics, mutations via multivariable analysis (Passamonti et al., 2009; Tefferi et al., 2014).
How PapersFlow Helps You Research Dynamic International Prognostic Scoring System for Myelofibrosis
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph on Passamonti et al. (2009) to map 951 citing works, revealing DIPSS-plus extensions; exaSearch uncovers 50+ validation studies in myelofibrosis; findSimilarPapers links to Tefferi et al. (2014) for molecular refinements.
Analyze & Verify
Analysis Agent applies readPaperContent to extract DIPSS variables from Passamonti et al. (2009), then runPythonAnalysis with pandas to recompute risk scores from survival data; verifyResponse via CoVe cross-checks claims against Tefferi (2020); GRADE grading scores evidence as high for PMF prognostication.
Synthesize & Write
Synthesis Agent detects gaps in DIPSS molecular integration (Tefferi et al., 2014), flags contradictions in blast transformation predictions; Writing Agent uses latexEditText, latexSyncCitations for Passamonti (2009), and latexCompile to generate risk-stratified tables; exportMermaid diagrams DIPSS variable flows.
Use Cases
"Run survival analysis on DIPSS variables from Passamonti 2009 dataset."
Research Agent → searchPapers(DIPSS) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas Kaplan-Meier curves) → matplotlib survival plot output.
"Draft LaTeX review of DIPSS-plus refinements with citations."
Research Agent → citationGraph(Passamonti 2009) → Synthesis → gap detection → Writing Agent → latexEditText → latexSyncCitations(Tefferi 2020) → latexCompile → PDF review.
"Find GitHub repos analyzing myelofibrosis prognostic models."
Research Agent → findSimilarPapers(Tefferi 2014) → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python scripts for DIPSS risk calculators.
Automated Workflows
Deep Research workflow scans 50+ DIPSS papers via searchPapers → citationGraph → structured report with GRADE scores on survival predictions (Passamonti et al., 2009). DeepScan's 7-step chain verifies cytokine integration (Tefferi et al., 2011) with CoVe checkpoints and runPythonAnalysis. Theorizer generates hypotheses on DIPSS-molecular hybrids from Tefferi (2020).
Frequently Asked Questions
What defines DIPSS for myelofibrosis?
DIPSS uses five dynamic variables: age >65 years, hemoglobin <10 g/dL, WBC >25×10^9/L, blasts ≥1%, constitutional symptoms, assigning 1-4 points for low to high risk (Passamonti et al., 2009).
What methods improve DIPSS?
DIPSS-plus adds karyotype, transfusion need, platelets <100×10^9/L; molecular versions incorporate CALR/ASXL1 mutations (Tefferi et al., 2014; Passamonti et al., 2017).
What are key DIPSS papers?
Foundational: Passamonti et al. (2009, 951 citations) introduces model; Tefferi et al. (2014, 709 citations) adds molecular data; recent: Tefferi (2020, 287 citations) updates PMF management.
What open problems exist in DIPSS?
Dynamic molecular updates, blast transformation accuracy, cytokine integration into scores; post-PV/ET subtypes need tailored models (Tefferi et al., 2011; Passamonti et al., 2017).
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Dynamic International Prognostic Scoring System for Myelofibrosis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers